Saturday 17 October 2026
Export RLAY’s income statement to Excel — free account
Relay Therapeutics, Inc.
RLAY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 95.4%, EPS was flat and free cash flow grew 2.13%, each against the same quarter a year earlier.
16.28
1.02
−5.90%
Follow RLAY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 57.24 | 97.49 | 344.21 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (32.36) | (35.01) | (70.14) | |
P/B ratio |
— | 2.56 | 2.79 | 4.26 | |
Price to Tangible BV |
— | 2.57 | 2.80 | 4.28 | |
EV/Sales |
— | 35.37 | 62.51 | 261.60 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (3.81) | (5.38) | (13.59) | |
EV/FCF |
— | (3.80) | (5.37) | (13.57) | |
Quick Ratio |
18.29 | 21.68 | 21.58 | 17.93 | |
Current Ratio |
19.14 | 22.61 | 22.13 | 18.27 | |
Net Debt/EBITDA |
7.39 | 9.11 | 8.14 | 10.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.03 | 0.02 | 0.01 | |
Operating CF/Net income |
0.84 | 0.82 | 0.70 | 0.65 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 791.76% | 2,352.10% | 21,852.29% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 174.52% | 367.57% | 4,197.43% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 186.70% | 351.23% | 2,622.57% | |
Graham Net Nets |
— | 0.36 | 0.34 | 0.22 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (19.15%) | (15.78%) | (8.39%) | |
Free Cash Flow Yield |
— | (16.25%) | (11.95%) | (5.60%) | |
Revenue per Share |
0.00 | 0.04 | 0.02 | 0.00 | |
Operating CF per Share |
(0.36) | (0.26) | (0.28) | (0.27) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.36) | (0.26) | (0.28) | (0.27) | |
Cash per Share |
3.46 | 3.23 | 3.57 | 4.49 | |
Shareholders Equity per Share |
3.53 | 3.30 | 3.57 | 4.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.53 | 3.30 | 3.57 | 4.39 | |
Free Cash Flow |
(62.12) | (44.87) | (51.11) | (54.11) | |
Working Capital |
591.41 | 552.70 | 628.71 | 877.28 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
561.72 | 524.01 | 601.03 | 850.63 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.81 | 10.90 | 6.28 | 8.32 | |
Average Assets |
800.06 | 746.31 | 749.49 | 848.15 | |
Average Common Equity |
723.28 | 672.43 | 681.63 | 777.83 |
Columns are period end dates